• +1-646-491-9876
    • +91-20-67278686

    Search

    Alopecia - Pipeline Review, H1 2017

    Alopecia - Pipeline Review, H1 2017

    • Report Code ID: RW0001689408
    • Category Healthcare
    • No. of Pages 156
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Alopecia - Pipeline Review, H1 2017, provides an overview of the Alopecia (Dermatology) pipeline landscape.

    Alopecia is the partial or complete loss of hair especially on the scalp either in patches, on the entire head or over the entire body. Thinning hair is the most obvious symptom. The predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Alopecia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 15, 4, 1, 18 and 8 respectively. Similarly, the Universities portfolio in Phase III and Discovery stages comprises 1 and 1 molecules, respectively.

    Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Alopecia (Dermatology).
    - The pipeline guide reviews pipeline therapeutics for Alopecia (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Alopecia (Dermatology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Alopecia (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Alopecia (Dermatology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Alopecia (Dermatology).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Alopecia (Dermatology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 4
    List of Figures 5
    Introduction 6
    Publisher Report Coverage 6
    Alopecia - Overview 7
    Alopecia - Therapeutics Development 8
    Pipeline Overview 8
    Pipeline by Companies 9
    Pipeline by Universities/Institutes 12
    Products under Development by Companies 13
    Products under Development by Universities/Institutes 16
    Alopecia - Therapeutics Assessment 17
    Assessment by Target 17
    Assessment by Mechanism of Action 20
    Assessment by Route of Administration 23
    Assessment by Molecule Type 25
    Alopecia - Companies Involved in Therapeutics Development 27
    Aclaris Therapeutics Inc 27
    Allergan Plc 27
    Almirall SA 28
    AndroScience Corp 28
    Berg LLC 29
    BiologicsMD Inc 29
    BirchBioMed Inc 30
    Bristol-Myers Squibb Company 30
    Cassiopea SpA 31
    Concert Pharmaceuticals Inc 31
    Dong-A Socio Holdings Co Ltd 32
    Follicum AB 32
    Handok Inc 33
    Histogen Inc 33
    Hyundai Pharmaceutical Co Ltd 34
    Incyte Corp 34
    Kuhnil Pharmaceutical Co Ltd 35
    Lee's Pharmaceutical Holdings Ltd 35
    LEO Pharma A/S 36
    Medivir AB 36
    NovaLead Pharma Pvt Ltd 37
    Novartis AG 37
    Panacea Biotec Ltd 38
    Pfizer Inc 38
    Quark Pharmaceuticals Inc 39
    RiverTown Therapeutics Inc 39
    RXi Pharmaceuticals Corp 40
    Samumed LLC 40
    SWITCH Biotech LLC 41
    Taisho Pharmaceutical Holdings Co Ltd 41
    Tigo GmbH 42
    viDA Therapeutics Inc 42
    Alopecia - Drug Profiles 43
    (cyclosporine A + minoxidil + RT-175) - Drug Profile 43
    abatacept - Drug Profile 44
    AI-001 - Drug Profile 51
    Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile 52
    Antisense Oligonucleotide to Inhibit Androgen Receptor for Alopecia - Drug Profile 53
    ASCJ-9 - Drug Profile 54
    ATI-50001 - Drug Profile 56
    ATI-50002 - Drug Profile 57
    ATI-50003 - Drug Profile 58
    bimatoprost - Drug Profile 59
    BMD-1141 - Drug Profile 61
    BMD-1341 - Drug Profile 62
    BMD-2341 - Drug Profile 63
    BQ-A - Drug Profile 64
    BRM-421 - Drug Profile 65
    calcitriol - Drug Profile 66
    CB-0301 - Drug Profile 67
    CTP-543 - Drug Profile 70
    DHL-HisZnNa - Drug Profile 72
    finasteride - Drug Profile 73
    finasteride - Drug Profile 74
    FOL-005 - Drug Profile 75
    HGEN-001 - Drug Profile 78
    HL-5945 - Drug Profile 80
    HTB-005 - Drug Profile 81
    interferon beta-1b - Drug Profile 82
    KI-1104 - Drug Profile 83
    KI-1105 - Drug Profile 84
    LEO-124249 - Drug Profile 85
    minoxidil - Drug Profile 86
    NLP-602 - Drug Profile 87
    OLX-104 - Drug Profile 88
    PF-06651600 - Drug Profile 89
    PF-06700841 - Drug Profile 90
    QPAL-1 - Drug Profile 92
    QPAL-2 - Drug Profile 93
    Recombinant Proteins to Antagonize IFN-Gamma Receptor 1 for Alopecia Areata and Graft Arteriosclerosis - Drug Profile 94
    remetinostat - Drug Profile 95
    ruxolitinib phosphate - Drug Profile 98
    Samcyprone - Drug Profile 113
    secukinumab - Drug Profile 115
    setipiprant - Drug Profile 128
    SM-04554 - Drug Profile 130
    Small Molecule for Androgenic Alopecia - Drug Profile 132
    Small Molecules to Inhibit JAK for Alopecia Areata, Androgenetic Alopecia and Dermatological Disorders - Drug Profile 133
    Synthetic Peptide for Alopecia - Drug Profile 134
    TASP-0382088 - Drug Profile 135
    TS-133 - Drug Profile 136
    VTI-1000 Series - Drug Profile 137
    ZK-003 - Drug Profile 138
    Alopecia - Dormant Projects 139
    Alopecia - Discontinued Products 141
    Alopecia - Product Development Milestones 142
    Featured News & Press Releases 142
    Appendix 151
    Methodology 151
    Coverage 151
    Secondary Research 151
    Primary Research 151
    Expert Panel Validation 151
    Contact Us 151
    Disclaimer 152

    List of Tables

    Number of Products under Development for Alopecia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Alopecia - Pipeline by Aclaris Therapeutics Inc, H1 2017
    Alopecia - Pipeline by Allergan Plc, H1 2017
    Alopecia - Pipeline by Almirall SA, H1 2017
    Alopecia - Pipeline by AndroScience Corp, H1 2017
    Alopecia - Pipeline by Berg LLC, H1 2017
    Alopecia - Pipeline by BiologicsMD Inc, H1 2017
    Alopecia - Pipeline by BirchBioMed Inc, H1 2017
    Alopecia - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Alopecia - Pipeline by Cassiopea SpA, H1 2017
    Alopecia - Pipeline by Concert Pharmaceuticals Inc, H1 2017
    Alopecia - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
    Alopecia - Pipeline by Follicum AB, H1 2017
    Alopecia - Pipeline by Handok Inc, H1 2017
    Alopecia - Pipeline by Histogen Inc, H1 2017
    Alopecia - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017
    Alopecia - Pipeline by Incyte Corp, H1 2017
    Alopecia - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2017
    Alopecia - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017
    Alopecia - Pipeline by LEO Pharma A/S, H1 2017
    Alopecia - Pipeline by Medivir AB, H1 2017
    Alopecia - Pipeline by NovaLead Pharma Pvt Ltd, H1 2017
    Alopecia - Pipeline by Novartis AG, H1 2017
    Alopecia - Pipeline by Panacea Biotec Ltd, H1 2017
    Alopecia - Pipeline by Pfizer Inc, H1 2017
    Alopecia - Pipeline by Quark Pharmaceuticals Inc, H1 2017
    Alopecia - Pipeline by RiverTown Therapeutics Inc, H1 2017
    Alopecia - Pipeline by RXi Pharmaceuticals Corp, H1 2017
    Alopecia - Pipeline by Samumed LLC, H1 2017
    Alopecia - Pipeline by SWITCH Biotech LLC, H1 2017
    Alopecia - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2017
    Alopecia - Pipeline by Tigo GmbH, H1 2017
    Alopecia - Pipeline by viDA Therapeutics Inc, H1 2017
    Alopecia - Dormant Projects, H1 2017
    Alopecia - Dormant Projects, H1 2017 (Contd..1), H1 2017
    Alopecia - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Alopecia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Aclaris Therapeutics Inc
    Allergan Plc
    Almirall SA
    AndroScience Corp
    Berg LLC
    BiologicsMD Inc
    BirchBioMed Inc
    Bristol-Myers Squibb Company
    Cassiopea SpA
    Concert Pharmaceuticals Inc
    Dong-A Socio Holdings Co Ltd
    Follicum AB
    Handok Inc
    Histogen Inc
    Hyundai Pharmaceutical Co Ltd
    Incyte Corp
    Kuhnil Pharmaceutical Co Ltd
    Lee's Pharmaceutical Holdings Ltd
    LEO Pharma A/S
    Medivir AB
    NovaLead Pharma Pvt Ltd
    Novartis AG
    Panacea Biotec Ltd
    Pfizer Inc
    Quark Pharmaceuticals Inc
    RiverTown Therapeutics Inc
    RXi Pharmaceuticals Corp
    Samumed LLC
    SWITCH Biotech LLC
    Taisho Pharmaceutical Holdings Co Ltd
    Tigo GmbH
    viDA Therapeutics Inc

    Request for Sample

    Report Url http://www.reportsweb.com//alopecia-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//alopecia-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//alopecia-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments